Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso

Antiviral Therapy

Volumn 13, Issue 1, 2008, Pages 141-148

  Sylla, Mohamed ^a   Chamberland, Annie ^a   Boileau, Catherine ^a   Traoré, Hamar A ^b   Ag Aboubacrine, Souleyman ^b   Cissé, Mamadou ^c   Koala, Samual ^d   Drabo, Joseph ^e   Diallo, Ismael ^e   Niamba, Pascal ^e   Tremblay Sher, Daniel ^a   Machouf, Nimâ ^a,f   Rashed, Sélim ^g   Nickle, David C ^h   Nguyen, Vinh Kim ^a,f   Tremblay, Cécile L ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Hopital National du Point G   (Mali)

^c CESAC   (Mali)

^d Centre Oasis/AAS   (Burkina Faso)

^e CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^f Clinique Medicale l'Actuel   (Canada)

^g MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BURKINA FASO; CITY; CLADISTICS; CLINICAL PROTOCOL; COHORT ANALYSIS; DIRECTLY OBSERVED THERAPY; FEMALE; GENETIC DISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALI; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; BURKINA FASO; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MALI; MUTATION; PHYLOGENY;

EID: 42149130823     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kuehn BM. UNAIDS report: AIDS epidemic slowing, but huge challenges remain. JAMA 2006; 296:29-30.
2. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003; 33:336-342.
3. + T-lymphocyte values in human immunodeficiency virus-negative adults in Botswana. Clin Diagn Lab Immunol 2004; 11:930-935.
4. Calazans A, Brindeiro R, Brindeiro P, et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005; 191:1961-1970.
5. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
6. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. Aids 2003; 17:F1-F5.
7. Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T, Wainberg MA. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses 2003; 19:743-753.
8. Grossman Z, Paxinos EE, Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48:2159-2165.
9. Thompson JD, Higgins DG, Gibson TJ. Clustal W improving the sensitivity of progressive multiple sequence alignment through sequence weighting poition specific gap penalties. Nucleic Acids Res 1994. 22:4693-4680.
10. Kumar M, Jain SK, Pasha ST, Chattopadhaya D, Lal S, Rai A. Genomic diversity in the regulatory nef gene sequences in Indian isolates of HIV type 1: emergence of a distinct subclade and predicted implications. AIDS Res Hum Retroviruses 2006; 22:1206-1219.
11. Slatkin M, Maddison WP. A cladistic measure of gene flow inferred from the phylogenies of alleles. Genetics 1989; 123:603-613.
12. Slatkin M, Maddison WP. Detecting isolation by distance using phylogenies of genes. Genetics 1990; 126:249-260.
13. Swofford DL. PAUP* 4.0: Phylogenetic Analysis Using Parsimony (*and Other Methods). Sunderland, MA: Sinauer Associates, Inc. 2002.
14. Maddison WP, Maddison DR. MacClade - Analysis of Phylogeny and Character Evolution - Version 4. Sunderland, MA: Sinauer Associates, Inc. 2001.
15. Hudson RR. A new statistic for detecting genetic differentiation. Genetics 2000; 155:2011-2014.
16. Laurent C, Bourgeois A, Faye MA, et al. No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study. J Infect Dis 2002; 186:486-492.
17. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29:184-190.
18. Triques K, Bourgeois A, Vidal N, et al. Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. AIDS Res Hum Retroviruses 2000; 16:139-151.
19. Nadembega WM, Giannella S, Simpore J, et al. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J Med Virol 2006; 78:1385-1391.
20. Tebit DM, Ganame J, Sathiandee K, Nagabila Y, Coulibaly B, Krausslich HG. Diversity of HIV in rural Burkina Faso. J Acquir Immune Defic Syndr 2006; 43:144-152.
21. McCutchan FE, Carr JK, Bajani M, et al. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology 1999; 254:226-234.
22. Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10:791-802.
23. Kuritzkes DR, Bassett RL, Hazelwood JD, et al. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr 2004; 36:600-603.
24. Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 2006; 80:7020-7027.